Last reviewed 2026-04-19 · How we verify

DIISOPROMINE

Phase 2 active Small molecule

DIISOPROMINE is a diisopromine drug. It is currently in Phase 2 development.

DIISOPROMINE works by interacting with a specific target in the body, but its exact mechanism is unknown.

DIISOPROMINE is a small molecule drug in the diisopromine class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, there is limited information available on its safety profile, pharmacokinetics, and generic availability. Further research is needed to fully understand this compound. Its development history is also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIISOPROMINE
Drug class	diisopromine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, we don't know how DIISOPROMINE works, but it's likely that it binds to a specific protein or receptor in the body, triggering a response that helps to treat a particular condition. This process is complex and involves many different molecules and cells working together. More research is needed to fully understand how DIISOPROMINE works.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DIISOPROMINE CI brief — competitive landscape report
DIISOPROMINE updates RSS · CI watch RSS

Frequently asked questions about DIISOPROMINE

What is DIISOPROMINE?

DIISOPROMINE is a diisopromine drug.

How does DIISOPROMINE work?

DIISOPROMINE works by interacting with a specific target in the body, but its exact mechanism is unknown.

What drug class is DIISOPROMINE in?

DIISOPROMINE belongs to the diisopromine class. See all diisopromine drugs at /class/diisopromine.

What development phase is DIISOPROMINE in?

DIISOPROMINE is in Phase 2.

Drug class: All diisopromine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing